Clinical Trial Update: A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating PROCRIT (epoetin alfa) versus placebo for neuroprotection in cancer patients who develop chemotherapy-induced peripheral neuropathy; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Peripheral Neuropathy, Chemotherapy-induced | Phase 2 | Status: TERMINATED | Results posted: 2009-09-07